Analyst spots more monkeypox opportunities for Bavarian

Ongoing dialogs with several governments strengthen one analyst’s belief in future orders for Bavarian Nordic’s monkeypox vaccine.

Depicted is a Bavarian Nordic employee in a German lab working on the firm's vaccine, which is the only approved vaccine in the world against monkeypox | Photo: LUKAS BARTH/REUTERS / X03379

Bavarian Nordic is in the middle of an order rush driven by the current outbreak of monkeypox across the world, and there is no sign of the source drying out any time soon.

Senior Equity Analyst at Sydbank Søren Løntoft Hansen points out that Bavarian is in talks with a number of countries concerning the firm’s vaccine, which is approved against monkeypox in the US and Canada, where it is branded Jynneos and Imvamune, respectively, and Imvanex in Europe, where it is only currently approved for the smallpox indication.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs